Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668976 | 0.92 | LMNA (0.43) | TAOK1TAOK3EPHX2PREPFAP | |
| SCHEMBL4387610 | 0.87 | KDM4E (0.42) | EPHX2HTTKMT2AL3MBTL1LMNA | |
| SCHEMBL4392436 | 0.86 | POLB (0.53) | EPHX2 | |
| SCHEMBL4541090 | 0.85 | EPHX2 (0.49) | TAOK1TAOK3EPHX2KMT2APREP | |
| SCHEMBL4541091 | 0.85 | EPHX2 (0.49) | TAOK1TAOK3EPHX2KMT2APREP | |
| SCHEMBL5670103 | 0.83 | TAOK1 (0.67) | TAOK1TAOK3TRPV1KMT2AL3MBTL1 | |
| SCHEMBL2173905 | 0.83 | SHMT2 (0.43) | TAOK1TAOK3HTTKMT2AALDH1A1 | |
| SCHEMBL2171393 | 0.82 | ALDH1A1 (0.42) | TAOK1TAOK3HTTKMT2ALMNA | |
| SCHEMBL2172250 | 0.82 | MEN1 (0.45) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5669968 | 0.82 | CYP1A2 (0.41) | TAOK1TAOK3HTTKMT2APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TAOK1 2409/4885TAOK3 1654/4885EPHX1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.